ArticleJournal of oral and maxillofacial pathology : JOMFP
Immunohistochemical evaluation of SOX9 expression in oral squamous cell carcinoma, pharyngeal and thyroid carcinomas.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) remains a major global health challenge with significant morbidity and mortality. While SOX9, a key transcription factor, has been implicated in cancer stem cell biology and treatment resistance, its expression patterns across different head and neck malignancies remain incompletely documented. Hence, the present study aimed to evaluate SOX9 expression across oral squamous cell carcinoma (OSCC), pharyngeal carcinoma, and thyroid carcinoma. Methods: A retrospective immunohistochemical analysis was performed on 90 tissue specimens (30 cases each of OSCC, pharyngeal carcinoma, and thyroid carcinoma). SOX9 expression was assessed for staining percentage, intensity, and subcellular localisation by two independent pathologists. Statistical analyses was performed using Chi-square and Kruskal-Wallis tests ( Results: Thyroid carcinoma exhibited the highest SOX9 expression, with 60% showing 76-100% positivity versus 13.3% in OSCC and 23.3% in pharyngeal carcinoma ( Conclusions: The present study shows that SOX9 behaves differently across head and neck cancers rising with tumour grade in squamous cell carcinomas but showing an inverse pattern in thyroid cancers, where high expression indicates well-differentiated tumours and decreases with dedifferentiation. These contrasting patterns suggest SOX9 could be a useful diagnostic and prognostic marker whose significance depends on cancer type.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.